CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on hepatocellular carcinoma (HCC), aiming to identify novel therapeutic targets and prognostic markers based on ultra-conserved non-coding RNAs. It seeks to understand their role in liver cancer progression and potential for use in treatment.
Hepatocellular carcinoma (HCC) is the sixth most common malignancy in the world.
In Scotland incidence of liver cancer has increased of 60% in men from 2000 to 2010.
The outcome of patients with advanced HCC remains poor.
Thus, novel therapeutic approaches based on targeting oncogenic driver pathways in HCC are urgently needed, as well as informative prognostic markers that guide the use of existing and novel therapeutic strategies.
Non-coding-RNAs (ncRNA) are implicated in liver carcinogenesis.…
INSTITUTE OF CANCER RESEARCH: THE ROYAL CANCER HOSPITAL LBG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Glasgow
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
